Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_1

29%

Ph phase_2

71%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution7 total trials

Phase 1Safety & dosage

2(28.6%)

Phase 2Efficacy & side effects

5(71.4%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Completed(3)

Detailed Status

Not yet recruiting4

Completed3

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 12 (28.6%)

Phase 25 (71.4%)

Trials by Status

not_yet_recruiting457%

completed343%

Recent Activity

0 active trials

Showing 5 of 7

not_yet_recruitingphase_2

24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease

NCT02579252

View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials

NCT07173803Phase 2

The Progressive Supranuclear Palsy Clinical Trial Platform

Not Yet Recruiting

NCT07217665Phase 2

The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1

Not Yet Recruiting

NCT06957418Phase 2

Alzheimer's Tau Platform: Master Protocol

Not Yet Recruiting

NCT07167966Phase 2

Alzheimer's Tau Platform: Regimen A - AADvac1

Not Yet Recruiting

NCT02579252Phase 2

24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease

Completed

NCT02031198Phase 1

18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease

Completed

NCT01850238Phase 1

Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease

Completed

All 7 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 7